Oxaliplatin and ototoxicity: is it really safe for hearing?

Oxaliplatin is an effective and widely used chemotherapeutic agent in the treatment of many solid tumors. The most common side effects are peripheral neuropathy, gastrointestinal toxicity, and neutropenia. There have been some case reports about ototoxicity with oxaliplatin, but no clinical trials. In this trial, we explored whether or not oxaliplatin has ototoxic effects. Materials and methods: A total of 18 patients, 14 with colorectal cancer and 4 with pancreatic cancer, were included in this study. Four patients (22%) were treated with a capecitabine and oxaliplatin (CapeOx) regimen, and 14 patients (78%) were treated with fluorouracil, leucovorin, and oxaliplatin (FOLFOX-6). Patients' pretreatment and posttreatment hearing levels were assessed with high-frequency audiometry and otoacoustic emission tests. Results: The median time between the first and the last oxaliplatin doses was 3.2 months (range: 2-7 months). There was no hearing loss in tests conducted for both ears of patients at frequencies of 500, 1000, 2000, 4000, 6000, 8000, 12,000, and 16,000 Hz. There was no difference between the pretreatment and posttreatment otoacoustic emission tests. Conclusion: Oxaliplatin is a reliable agent in terms of ototoxicity.

Oxaliplatin and ototoxicity: is it really safe for hearing?

Oxaliplatin is an effective and widely used chemotherapeutic agent in the treatment of many solid tumors. The most common side effects are peripheral neuropathy, gastrointestinal toxicity, and neutropenia. There have been some case reports about ototoxicity with oxaliplatin, but no clinical trials. In this trial, we explored whether or not oxaliplatin has ototoxic effects. Materials and methods: A total of 18 patients, 14 with colorectal cancer and 4 with pancreatic cancer, were included in this study. Four patients (22%) were treated with a capecitabine and oxaliplatin (CapeOx) regimen, and 14 patients (78%) were treated with fluorouracil, leucovorin, and oxaliplatin (FOLFOX-6). Patients' pretreatment and posttreatment hearing levels were assessed with high-frequency audiometry and otoacoustic emission tests. Results: The median time between the first and the last oxaliplatin doses was 3.2 months (range: 2-7 months). There was no hearing loss in tests conducted for both ears of patients at frequencies of 500, 1000, 2000, 4000, 6000, 8000, 12,000, and 16,000 Hz. There was no difference between the pretreatment and posttreatment otoacoustic emission tests. Conclusion: Oxaliplatin is a reliable agent in terms of ototoxicity.

___

  • André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343– 23
  • Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN G et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198–2204.
  • André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109–3116.
  • Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299–303.
  • Saif MW, Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 2005; 1: 249– 2
  • Moroso M, Blair R. A review of cis-platinum ototoxicity. J Otolaryngol 1983; 12: 356–359.
  • Seligman H, Podoshin L, Ben-David J, Fradis M, Goldsher M. Drug-induced tinnitus and other hearing disorders. Drug Saf 1996; 14: 198–212.
  • Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersall MH. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep 1982; 66: 19–23.
  • Şanlı A, Aydın S, Sarısoy ZA, Paksoy M, Ayduran E, Çelebi Erdivanlı Ö. The protective effect of dexamethasone and lactate against cisplatin-induced ototoxicity. Turk J Med Sci 2011; 41: 467–474.
  • Dutta A, Venkatesh MD, Kashyap RC. Study of the effects of chemotherapy on auditory function. Indian J Otolaryngol Head Neck Surg 2005; 57: 226–228.
  • Kennedy IC, Fitzharris BM, Colls BM, Atkinson CH. Carboplatin is ototoxic. Cancer Chemother Pharmacol 1990; 26: 232–234.
  • Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9–23.
  • Montaguti M, Brandolini C, Ferri GG, Hatzopoulos S, Prete A, Pession A. Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention. Acta Otorhinolaryngol Ital 2002; 22: 14–18.
  • Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, Martoni A, Grothey A, Hinke A, Schmiegel W et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008; 26: 5910–5917.
  • Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, Díaz-Rubio E, Gilberg F, Cassidy J. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy Ann Oncol 2012; 23: 1190–1197.
  • Hellberg V, Wallin I, Eriksson S, Hernlund E, Jerremalm E, Berndtsson M, Eksborg S, Arnér ES, Shoshan M, Ehrsson H et al. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst 2009; 101: 37–47.
Turkish Journal of Medical Sciences-Cover
  • ISSN: 1300-0144
  • Yayın Aralığı: Yılda 6 Sayı
  • Yayıncı: TÜBİTAK
Sayıdaki Diğer Makaleler

Clinical and demographic findings of patients with rheumatoid arthritis and ankylosing spondylitis treated in a tertiary care center in Turkey

Özlem CEMEROĞLU, Zeynep Sıla YAŞAR, Mustafa SAĞLAM, Haşim ÇAKIRBAY

Early graft dysfunction and mortality rate in marginal donor liver transplantation

Pınar SARKUT, Barış GÜLCÜ, Remzi İŞÇİMEN, Murat KIYICI, Gürkan TÜRKER

Effects of linoleic acid on generalized convulsive and nonconvulsive epileptic seizures

Fatih EKİCİ, Gönül GÜROL, Nurbay ATEŞ

The effect of lycopene on the ototoxicity induced by cisplatin*

Tuba BAYINDIR, Mahmut Tayyar KALCIOĞLU, Mehmet Turan ÇİÇEK, Mustafa IRAZ, Yüksel TOPLU

Migraine prevalence, disability, and sociodemographic properties in the eastern region of Turkey: a population-based door-to-door survey

Gökhan ÖZDEMİR, Recep AYGÜL, Recep DEMİR, Lütfi ÖZEL, Ayfer ERTEKİN, Hızır ULVİ

Attitudes towards influenza vaccination in high socioeconomic status Turkish parents

Suzan GÜNDÜZ, Çiğdem Nüket YÜKSEL, Hale Bozkurt AKTOPRAK, Metin CANBAL, Mehmet KAYA

Genotype distribution of hepatitis C virus in Khorasan Razavi Province, Iran

Reza AFSHARI, Hosein NOMANI, Fatemeh Riyahi ZANIANI, Maryam Sadat NABAVINIA

Effect of Ginkgo biloba on brain volume after carotid artery occlusion in rats: a stereological and histopathological study

Zeynep AKTÜRK, Ersan ODACI, Ayşe İKİNCİ, Orhan BAŞ, Sinan CANPOLAT

Clonal comparison of Acinetobacter strains isolated from intensive care patients and the intensive care unit environment

Esra KIRKGÖZ, Yasemin ZER

Evaluation of histopathologic and histomorphometric changes of testicular tissue and gonadotropin levels following consumption of methylphenidate in male mice

Simin FAZELIPOUR, Zahra TOOTIAN, Zahra GHAHRI SAREMI, Minoo SHAFII, Mohammad Taghi SHEIBANI, Seyed Babak KIAEI, Mehrnush KIUMARSI, Fardin ASSADI